Evidence map›Paper›PMID 35454393›Full record

ArticleMedicina (Kaunas, Lithuania)2022

Impact of the Rapid Normalization of Chronic Hyperglycemia on the Receptor Activator of Nuclear Factor-Kappa B Ligand and the Osteoprotegerin System in Patients Living with Type 2 Diabetes: RANKL-GLYC Study.

Dured Dardari, Claire Thomas, Francois-Xavier Laborne, Caroline Tourte, Elodie Henry, Megane Erblang, Stéphanie Bourdon, Alfred Penfornis, Philippe Lopes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medicina (Kaunas, Lithuania), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Dured DardariCentre Hopitalier Sud Francilien, Department of Diabetes, Hôpital Sud Francilien, 9110 Corbeil-Essonnes, France.
Claire ThomasLaboratoire de Biologie de l'Exercice pour la Performance et la Santé (LBEPS), Univ Evry, Université Paris Saclay, 91025 Evry, France.
Francois-Xavier LaborneCentre Hospitalier Sud Francilien, Unité de Recherhce Clinique, Hôpital Sud Francilien, 9110 Corbeil-Essonnes, France.
Caroline TourteCentre Hospitalier Sud Francilien, Unité de Recherhce Clinique, Hôpital Sud Francilien, 9110 Corbeil-Essonnes, France.
Elodie HenryCentre Hospitalier Sud Francilien, Unité de Recherhce Clinique, Hôpital Sud Francilien, 9110 Corbeil-Essonnes, France.
Megane ErblangUnité de Physiologie des Exercices et Activités en Conditions Extrêmes, Département Environnements Opérationnels, Institut de Recherche Biomédicale des Armées (IRBA), Université Paris Saclay, 91000 Evry, France.
Stéphanie BourdonParis-Sud Medical School, Université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France.
Alfred PenfornisCentre Hopitalier Sud Francilien, Department of Diabetes, Hôpital Sud Francilien, 9110 Corbeil-Essonnes, France.
Philippe LopesLaboratoire de Biologie de l'Exercice pour la Performance et la Santé (LBEPS), Univ Evry, Université Paris Saclay, 91025 Evry, France.
Centre Hospitalier Sud Francilien · FRUniversité Paris-Saclay · FRLaboratoire de Biologie de l'Exercice pour la Performance et la Santé

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The RANKL-GLYC study aims to explore the impact of the rapid correction of chronic hyperglycemia on the receptor activator of nuclear factor-kappa B ligand (RANKL) and its antagonist osteoprotegerin (OPG). RANKL and OPG are considered the main factors in the pathophysiology of Charcot neuroarthropathy, a devastating complication of the joints that remains poorly understood. The study began recruiting patients in September 2021 and ends in June 2022; the final study results are scheduled for January 2023.

Indexed as

Diabetes Mellitus, Type 2HyperglycemiaChronic DiseaseHumansNF-kappa BOsteoprotegerinRANK LigandReceptor Activator of Nuclear Factor-kappa BNF-kappa BOsteoprotegerinRANK LigandReceptor Activator of Nuclear Factor-kappa BCharcot neuroarthropathydiabetesHbA1costeoprotegerin (OPG)receptor activator of nuclear factor-kappa B ligand (RANKL)

Identifiers

PMID35454393
PMCPMC9029471
OpenAlexW4224270607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.